Navigation Links
Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
Date:8/19/2010

p> "These results reveal that radioembolisation using SIR-Spheres is a promising therapy for patients with colorectal cancer liver metastases who have failed chemotherapy," said Prof. Maurizio Cosimelli, Professor of Surgery at the Regina Elena National Cancer Institute in Rome, and co-ordinator of the study. "The prolonged 12.6-month median survival and encouraging tumour response reported in the SITILO study compares favourably with the clinical trial results of second- or third-line chemotherapy, even though three-quarters of our patients had previously received at least four different combinations of chemotherapy drugs and therefore had a poor prognosis with no other treatment options available."

"At a minimum, patients with liver-only or liver-dominant colorectal cancer who are failing chemotherapy and who remain fit should be considered for radioembolisation using SIR-Spheres," said Prof. Cosimelli. "However, SITILO will be conducting a multi-centre randomised trial using SIR-Spheres in combination with chemotherapy at an earlier line of treatment since we believe that this may further improve the prognosis for patients with colorectal liver metastases. Above all, it will be possible to clarify the potential of SIRT together with chemotherapy to increase the rate of surgical resections in patients that were previously unresectable."

Patients in the SITILO study had to have liver metastases from colorectal cancer that could not be removed by surgery and which had progressed despite modern chemotherapy regimens containing oxaliplatin and irinotecan. The presence of metastases outside the liver did not exclude the patients from treatment as long as these were limited in number, size and in the same organ. All patients were heavily pre-treated, having received at least 3 previous chemotherapy regimens: 24% had received 3 different lines or courses of chemotherapy, 50% had received 4 lines and 26% had received 5 lines.

The SITILO study used
'/>"/>

SOURCE Sirtex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass Fiber ... defines and segments the specialty synthetic fibers and ... of the volumes and values of types such ... UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile fiber, ... fiber, and liquid crystal polymer fiber and glass ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... Ticket Down is a reliable source ... When it comes to the summer concert schedule, it just ... native is one of the biggest names in country music and ... currently out on his “That’s My Kind of Night” tour featuring ... will be making through the rest of the summer and into ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... 31 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... are scheduled to present at the,Canaccord Adams 28th Annual ... p.m. Eastern Time. The Canaccord Adams 28th Annual Global,Growth ... Boston,Massachusetts., To access the webcast, go to the ...
... Call Today at 5:00 p.m. Eastern Time -, ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... progress and financial results,for the second quarter ended ... are to develop picoplatin as an oncology,platform compound ...
... July 31 Mylan Inc. (NYSE: MYL ),today ... stock,issuance, the company has declared its quarterly dividend of ... 6.5% and a liquidation,preference of $1,000.00 per share) payable ... record as of August 1, 2008., Mylan Inc., ...
... PARAMUS, N.J., July 31 Smart Balance Inc.,(Nasdaq: ... marketing organization,today. Richard McWilliams has been named to ... brands, reporting to Gregory Venner, executive,vice president and ... the marketing efforts for the Company,s core brands., ...
... ARBOR, Mich. Pat Phalin learned she had hearing loss ... her local school. The pupils heard sounds she could not ... a pattern in his wife,s family history. Her mother, grandfather ... the Phalins, children had hearing problems before he reached school ...
... ST. LOUIS, July 31 Stereotaxis, Inc. (Nasdaq:,STXS) ... results for the,second quarter ended June 30, 2008, ... The Company will host a conference call and ... Eastern Time to discuss the Company,s,second quarter results ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 2Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 3Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 4Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 5Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 6Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 7Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 8Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 9Health News:Smart Balance Announces Marketing Organization Appointment 2Health News:Inherited form of hearing loss stems from gene mutation 2Health News:Inherited form of hearing loss stems from gene mutation 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: